Creating a Comprehensive Treatment Plan for Hereditary Angioedema

Immunology and Allergy Clinics of North America

Volumn 33, Issue 4, 2013, Pages 471-485

  Riedl, Marc A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

C1INH deficiency; Hereditary angioedema; Therapy; Treatment plan

Indexed keywords

AMINOCAPROIC ACID; ANDROID; COMPLEMENT COMPONENT C1S INHIBITOR; DANACRINE; DANAZOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ECALLANTIDE; ESTROGEN; ICATIBANT; LIPID; LIVER ENZYME; METHYLTESTOSTERONE; OXANDROLONE; STANOZOLOL; TRANEXAMIC ACID; UNCLASSIFIED DRUG;

ACNE; ANGIONEUROTIC EDEMA; CHRONIC DISEASE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CONCEPTUAL FRAMEWORK; CONSENSUS; CONSTIPATION; DEPRESSION; DIAGNOSTIC ERROR; DISABILITY; DISEASE ASSOCIATION; DISEASE DURATION; DRUG APPROVAL; DRUG MECHANISM; EARLY INTERVENTION; EMERGENCY CARE; FATIGUE; FOLLOW UP; GROWTH RATE; HEADACHE; HEALTH CARE FACILITY; HEALTH CARE SYSTEM; HEALTH PROGRAM; HUMAN; HYPERTENSION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; ISCHEMIA; LIBIDO; LIVER ADENOMA; MEDICAL CARE; MEDICAL SPECIALIST; MENSTRUATION DISORDER; MORBIDITY; MORTALITY; MYALGIA; NAUSEA; OBSTRUCTIVE JAUNDICE; PARTIAL THROMBOPLASTIN TIME; PATIENT CARE PLANNING; PATIENT COUNSELING; PATIENT EDUCATION; PATIENT MONITORING; PATIENT SAFETY; PELIOSIS HEPATIS; PRESCRIPTION; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; RELIABILITY; REVIEW; RISK FACTOR; RISK REDUCTION; SELF CARE; SIDE EFFECT; SUFFOCATION; SYMPTOM; TREATMENT INDICATION; TREATMENT RESPONSE; VIRILIZATION; WEIGHT GAIN;

C1INH DEFICIENCY; HEREDITARY ANGIOEDEMA; THERAPY; TREATMENT PLAN;

ANGIOEDEMAS, HEREDITARY; COUNSELING; DISEASE MANAGEMENT; FOLLOW-UP STUDIES; HUMANS; PATIENT EDUCATION AS TOPIC;

EID: 84886724881     PISSN: 08898561     EISSN: 15578607     Source Type: Journal    
DOI: 10.1016/j.iac.2013.07.003     Document Type: Review

References (46)

1. Zuraw B.L. Clinical practice. Hereditary angioedema. NEngl J Med 2008, 359:1027-1036.
2. Donaldson V.H., Evans R.R. Abiochemical abnormality in hereditary angioneurotic edema: absence of serum inhibitor of C'1-esterase. Am J Med 1963, 35:37-44.
3. Rosen F.S., Pensky J., Donaldson V., et al. Hereditary angioneurotic edema: two genetic variants. Science 1965, 148:957-958.
4. Bork K., Barnstedt S.E., Koch P., et al. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet 2000, 356:213-217.
5. Bork K., Hardt J., Witzke G. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. JAllergy Clin Immunol 2012, 130:692-697.
6. Roche O., Blanch A., Caballero T., et al. Hereditary angioedema due to C1 inhibitor deficiency: patient registry and approach to the prevalence in Spain. Ann Allergy Asthma Immunol 2005, 94(4):498-503.
7. Bygum A. Hereditary angio-oedema in Denmark: a nationwide survey. Br J Dermatol 2009, 161(5):1153-1158.
8. Frank M.M., Gelfand J.A., Atkinson J.P. Hereditary angioedema: the clinical syndrome and its management. Ann Intern Med 1976, 84(5):580-593.
9. Farkas H. Current pharmacotherapy of bradykinin-mediated angioedema. Expert Opin Pharmacother 2013, 14(5):571-586.
10. Kaplan A.P. Enzymatic pathways in the pathogenesis of hereditary angioedema: the role of C1 inhibitor therapy. JAllergy Clin Immunol 2010, 126(5):918-925.
11. Bork K., Davis-Lorton M. Overview of hereditary angioedema caused by C1-inhibitor deficiency: assessment and clinical management. Eur Ann Allergy Clin Immunol 2013, 45(1):7-16.
12. Parikh N., Riedl M.A. New therapeutics in C1INH deficiency: a review of recent studies and advances. Curr Allergy Asthma Rep 2011, 11(4):300-308.
13. Bowen T., Cicardi M., Farkas H., et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 2010, 6:24.
14. Cicardi M., Bork K., Caballero T., et al. Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy 2012, 67:147-157.
15. Craig T., Pursun E.A., Bork K., et al. WAO guideline for the management of hereditary angioedema. World Allergy Organ J 2012, 5:182-199.
16. Lang D.M., Aberer W., Bernstein J.A., et al. International consensus on hereditary and acquired angioedema. Ann Allergy Asthma Immunol 2012, 109(6):395-402.
17. Craig T.J. Recent advances in hereditary angioedema self-administration treatment: summary of an international hereditary angioedema expert meeting. Int Arch Allergy Immunol 2013, 161(Suppl 1):26-27.
18. Aygören-Pürsün E., Martinez-Saguer I., Rusicke E., et al. On demand treatment and home therapy of hereditary angioedema in Germany-the Frankfurt experience. Allergy Asthma Clin Immunol 2010, 6(1):21.
19. Zingale L.C., Beltrami L., Zanichelli A., et al. Angioedema without urticaria: a large clinical survey. CMAJ 2006, 175(9):1065-1070.
20. Bork K., Meng G., Staubach P., et al. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med 2006, 119(3):267-274.
21. Reshef A., Prematta M.J., Craig T.J. Signs and symptoms preceding acute attacks of hereditary angioedema: results of three recent surveys. Allergy Asthma Proc 2013, 34(3):261-266.
22. Agostoni A., Aygören-Pürsün E., Binkley K.E., et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. JAllergy Clin Immunol 2004, 114(Suppl 3):S51-S131.
23. Bygum A., Aygören-Pürsün E., Caballero T., et al. The hereditary angioedema burden of illness study in Europe (HAE-BOIS-Europe): background and methodology. BMC Dermatol 2012, 12:4.
24. Lumry W.R., Castaldo A.J., Vernon M.K., et al. The humanistic burden of hereditary angioedema: impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc 2010, 31(5):407-414.
25. Cicardi M., Banerji A., Bracho F., et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. NEngl J Med 2010, 363:532-541.
26. Cicardi M., Levy R.J., McNeil D.L., et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. NEngl J Med 2010, 363:523-531.
27. Zuraw B.L., Busse P.J., White M., et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. NEngl J Med 2010, 363:513-522.
28. Craig T.J., Levy R.J., Wasserman R.L., et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. JAllergy Clin Immunol 2009, 124:801-808.
29. Zuraw B., Cicardi M., Levy R.J., et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. JAllergy Clin Immunol 2010, 126(4):821-827.
30. Tourangeau L.M., Castaldo A.J., Davis D.K., et al. Safety and efficacy of physician-supervised self-managed C1 inhibitor replacement therapy. Int Arch Allergy Immunol 2012, 157:417-424.
31. Levi M., Choi G., Picavet C., et al. Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency. JAllergy Clin Immunol 2006, 117:904-908.
32. Longhurst H.J., Farkas H., Craig T., et al. HAE international home therapy consensus document. Allergy Asthma Clin Immunol 2010, 6:22.
33. Riedl M.A., Hurewitz D.S., Levy R., et al. Nanofiltered C1 esterase inhibitor (human) for the treatment of acute attacks of hereditary angioedema: an open-label trial. Ann Allergy Asthma Immunol 2012, 108(1):49-53.
34. Banta E., Horn P., Craig T.J. Response to ecallantide treatment of acute attacks of hereditary angioedema based on time to intervention: results from the EDEMA clinical trials. Allergy Asthma Proc 2011, 32(4):319-324.
35. Maurer M., Aberer W., Bouillet L., I O S Investigators, et al. Hereditary angioedema attacks resolve faster and are shorter after early icatibant treatment. PLoS One 2013, 8(2):e53773. 10.1371/journal.pone.0053773.
36. Li H.H., Campion M., Craig T.J., et al. Analysis of hereditary angioedema attacks requiring a second dose of ecallantide. Ann Allergy Asthma Immunol 2013, 110(3):168-172.
37. Gower R.G., Busse P.J., Aygören-Pürsün E., et al. Hereditary angioedema caused by C1-esterase inhibitor deficiency: a literature-based analysis and clinical commentary on prophylaxis treatment strategies. World Allergy Organ J 2011, 4(Suppl 2):S9-S21.
38. Gower R.G., Lumry W.R., Davis-Lorton M.A., et al. Current options for prophylactic treatment of hereditary angioedema in the United States: patient-based considerations. Allergy Asthma Proc 2012, 33(3):235-240.
39. Craig T., Riedl M., Dykewicz M.S., et al. When is prophylaxis for hereditary angioedema necessary?. Ann Allergy Asthma Immunol 2009, 102:366-372.
40. Zuraw B.L., Kalfus I. Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema. Am J Med 2012, 125(9):938.e1-938.e7.
41. Füst G., Farkas H., Csuka D., et al. Long-term efficacy of danazol treatment in hereditary angioedema. Eur J Clin Invest 2011, 41(3):256-262.
42. Maurer M., Magerl M. Long-term prophylaxis of hereditary angioedema with androgen derivates: a critical appraisal and potential alternatives. JDtsch Dermatol Ges 2011, 9(2):99-107.
43. Gandhi P.K., Gentry W.M., Bottorff M.B. Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database. Pharmacotherapy 2012, 32(10):902-909.
44. Bork K., Bygum A., Hardt J. Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Ann Allergy Asthma Immunol 2008, 100(2):153-161.
45. Zilberberg M.D., Nathanson B.H., Jacobsen T., et al. Descriptive epidemiology of hereditary angioedema emergency department visits in the United States, 2006-2007. Allergy Asthma Proc 2011, 32(5):390-394.
46. Frank M.M. Hereditary angioedema: short-term prophylaxis for surgery. Allergy Asthma Proc 2012, 33(4):303-304.